Evommune (EVMN) Net Cash Flow (2024 - 2026)

Evommune (EVMN) has reported Net Cash Flow for 3 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 140.27% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $10.9 million (changed N/A YoY), while the FY2025 annual figure was $29.0 million, up 327.23% from the prior year.
• Net Cash Flow fell to $4.2 million in Q1 2026 per EVMN's latest filing, from $17.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $17.2 million in Q4 2025 and bottomed at -$10.6 million in Q1 2025.
• Historically, Net Cash Flow has averaged $2.3 million across 3 years, with a median of $1.2 million in 2024.
• Annual changes were most pronounced in 2025 — Net Cash Flow surged 1012.11% — and 2026, when it surged 140.27%.
• Evommune's Net Cash Flow stood at -$1.9 million in 2024, then soared by 1012.11% to $17.2 million in 2025, then slumped by 75.37% to $4.2 million in 2026.
• Business Quant data shows EVMN's Net Cash Flow at $4.2 million in Q1 2026, $17.2 million in Q4 2025, and -$10.6 million in Q1 2025.